Drug intelligence / Profile preview

OT-601-C

Development stage: Unknown
Lead developer: Ocumension Biotech
Modality: Small Molecules
Administration: Ophthalmic

Overview

**OT-601-C** is an ophthalmic fixed-dose combination of the fluoroquinolone antibacterial moxifloxacin and the corticosteroid dexamethasone sodium phosphate, developed by Ocumension with Hangzhou Minsheng Pharmaceutical. It is formulated as eye drops for postoperative ocular inflammation, including inflammation following cataract surgery, in settings where bacterial infection is present or poses a risk. Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone activates the glucocorticoid receptor to suppress inflammatory signaling.

Other names: moxifloxacin-dexamethasone sodium phosphate

Targets

GR (Glucocorticoid receptor)DNA gyraseTopo IV (Bacterial Topoisomerase IV)

Beyond the preview

Go deeper on OT-601-C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-601-C.

Explore the full profile